Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

The FDA Modernization Act of 1997 established the Fast Track designation to expedite developing and reviewing new drugs ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

The FDA allows companies to produce and market compounded ... Hims & Hers (HIMS) said it has been communicating information compiled through the tracker to state and federal agencies.

"Fast Track designation from the FDA underscores the serious unmet medical need in patients with widespread, debilitating diseases like OA," said Thomas Chalberg, Ph.D., founder and CEO of Genascence.